Dallas, TX5 Active Studies

Retinitis Pigmentosa Clinical Trials in Dallas, TX

Find 5 actively recruiting retinitis pigmentosa clinical trials in Dallas, TX. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
380
Enrolling

Recruiting Retinitis Pigmentosa Studies in Dallas

NCT07570979Recruiting

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination...

Dallas, TXPHASE1208 participantsNovartis Pharmaceuticals
View Study Details
NCT07710196Recruiting

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety o...

Dallas, TXPHASE380 participantsNacuity Pharmaceuticals, Inc.
View Study Details
NCT06789445Recruiting

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 5...

Dallas, TXPHASE154 participantsBlueRock Therapeutics
View Study Details
NCT07536269Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH....

Dallas, TXPHASE220 participantsNeurocrine Switzerland GmbH
View Study Details
NCT07408232Recruiting

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP...

Dallas, TXPHASE118 participantsOctant, Inc.
View Study Details

About Retinitis Pigmentosa Clinical Trials in Dallas

Retinitis pigmentosa (RP) is a group of inherited retinal diseases that cause progressive loss of photoreceptor cells in the retina, leading to vision loss. It typically begins with night blindness and progresses to tunnel vision. Gene therapy and retinal implants are areas of active research.

There are currently 5 retinitis pigmentosa clinical trials recruiting participants in Dallas, TX. These studies are seeking a combined 380 participants. Research is being sponsored by Novartis Pharmaceuticals, Nacuity Pharmaceuticals, Inc., BlueRock Therapeutics and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Retinitis Pigmentosa Clinical Trials in Dallas — FAQ

Are there retinitis pigmentosa clinical trials in Dallas?

Yes, there are 5 retinitis pigmentosa clinical trials currently recruiting in Dallas, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Dallas?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you about next steps.

Are clinical trials in Dallas free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dallas studies also compensate for your time and travel.

What retinitis pigmentosa treatments are being tested?

The 5 active trials in Dallas are testing new therapies including novel drugs, biologics, and treatment approaches for retinitis pigmentosa.

Data updated October 15, 2026 from ClinicalTrials.gov